367 related articles for article (PubMed ID: 26633641)
1. Nondaily preexposure prophylaxis for HIV prevention.
Anderson PL; García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2016 Jan; 11(1):94-101. PubMed ID: 26633641
[TBL] [Abstract][Full Text] [Related]
2. In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?
Mitchell KM; Dimitrov D; Hughes JP; Xia F; Donnell D; Amico KR; Bokoch K; Chitwarakorn A; Bekker LG; Holtz TH; Mannheimer S; Grant RM; Boily MC
AIDS; 2018 Mar; 32(6):809-818. PubMed ID: 29424774
[TBL] [Abstract][Full Text] [Related]
3. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
4. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
5. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
[TBL] [Abstract][Full Text] [Related]
6. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
7. Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
Koss CA; Liu AY; Castillo-Mancilla J; Bacchetti P; McHugh C; Kuncze K; Morrow M; Louie A; Seifert S; Okochi H; MaWhinney S; Gandhi M; Anderson PL
AIDS; 2018 Sep; 32(15):2189-2194. PubMed ID: 30212404
[TBL] [Abstract][Full Text] [Related]
8. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
11. Animal models of antiretroviral prophylaxis for HIV prevention.
García-Lerma JG; Heneine W
Curr Opin HIV AIDS; 2012 Nov; 7(6):505-13. PubMed ID: 22964889
[TBL] [Abstract][Full Text] [Related]
12. Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.
Thaden JT; Gandhi M; Okochi H; Hurt CB; McKellar MS
AIDS; 2018 Jun; 32(9):F1-F4. PubMed ID: 29683856
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
Koss CA; Hosek SG; Bacchetti P; Anderson PL; Liu AY; Horng H; Benet LZ; Kuncze K; Louie A; Saberi P; Wilson CM; Gandhi M
Clin Infect Dis; 2018 Jan; 66(2):213-219. PubMed ID: 29020194
[TBL] [Abstract][Full Text] [Related]
14. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
15. HPTN 067/ADAPT: Correlates of Sex-Related Pre-exposure Prophylaxis Adherence, Thai Men Who Have Sex With Men, and Transgender Women, 2012-2013.
Holtz TH; Chitwarakorn A; Hughes JP; Curlin ME; Varangrat A; Li M; Amico KR; Mock PA; Grant RM;
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):e18-e26. PubMed ID: 31490342
[TBL] [Abstract][Full Text] [Related]
16. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM
AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403
[TBL] [Abstract][Full Text] [Related]
17. The European preexposure prophylaxis revolution.
Cairns G; McCormack S; Molina JM
Curr Opin HIV AIDS; 2016 Jan; 11(1):74-9. PubMed ID: 26599164
[TBL] [Abstract][Full Text] [Related]
18. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
Thomson KA; Baeten JM; Mugo NR; Bekker LG; Celum CL; Heffron R
Curr Opin HIV AIDS; 2016 Jan; 11(1):18-26. PubMed ID: 26417954
[TBL] [Abstract][Full Text] [Related]
20. Considerations regarding antiretroviral chemoprophylaxis in MSM.
Poynten IM; Zablotska I; Grulich AE
Curr Opin HIV AIDS; 2012 Nov; 7(6):549-56. PubMed ID: 22918448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
